User:Mr. Ibrahem/Ibrutinib

From Wikipedia, the free encyclopedia
Mr. Ibrahem/Ibrutinib
Clinical data
Trade namesImbruvica, others
Other namesPCI-32765, CRA-032765
AHFS/Drugs.comMonograph
MedlinePlusa614007
License data
Pregnancy
category
Routes of
administration		By mouth (capsules)
Legal status
Legal status
  • AU: S4 (Prescription only)
  • UK: POM (Prescription only)[2][3]
  • US: ℞-only[4]
  • EU: Rx-only[5]
  • In general: ℞ (Prescription only)
Pharmacokinetic data
Protein binding97.3%
MetabolismLiver (CYP3A & CYP2D6)
Elimination half-life4–6 hours
ExcretionFeces (80%), urine (10%)
Identifiers
  • 1-[(3R)-3-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidin-1-yl]prop-2-en-1-one
Chemical and physical data
FormulaC25H24N6O2
Molar mass440.507 g·mol−1
3D model (JSmol)
  • C=CC(=O)N1CCC[C@H](C1)N2C3=C(C(=N2)C4=CC=C(C=C4)OC5=CC=CC=C5)C(=NC=N3)N
  • InChI=1S/C25H24N6O2/c1-2-21(32)30-14-6-7-18(15-30)31-25-22(24(26)27-16-28-25)23(29-31)17-10-12-20(13-11-17)33-19-8-4-3-5-9-19/h2-5,8-13,16,18H,1,6-7,14-15H2,(H2,26,27,28)/t18-/m1/s1
  • Key:XYFPWWZEPKGCCK-GOSISDBHBU

Ibrutinib, sold under the brand name Imbruvica among others, is a medication used to treat mantle cell lymphoma (MCL), chronic lymphocytic leukemia (CLL), and Waldenström's macroglobulinemia.[4][5] It is used in MCL and CLL when other treatments have failed.[5] Other uses may include graft versus host disease.[4] It is taken by mouth.[4]

Common side effects include low platelets, low red blood cells, low white blood cells, diarrhea, rash, bleeding, and mouth inflammation.[4] Other side effects may include infection, heart failure, high blood pressure, other cancers, and tumor lysis syndrome.[4] Use in pregnancy may harm the baby.[4] It works by blocking Bruton's tyrosine kinase (BTK) which slows B cell division.[5]

Ibrutinib was approved for medical use in the United States in 2013 and Europe in 2014.[6][5] It is on the World Health Organization's List of Essential Medicines as a complementary item.[7] Generic versions have been approved.[8] In the United Kingdom 4 weeks of treatment costs the NHS about £5,000 as of 2021.[9] This amount in the United States costs about 14,500 USD.[10]

References[edit]

  1. ^ "Ibrutinib (Imbruvica) Use During Pregnancy". Drugs.com. 3 December 2019. Archived from the original on 28 March 2020. Retrieved 28 March 2020.
  2. ^ "Imbruvica 140 mg Film-Coated Tablets - Summary of Product Characteristics (SmPC)". (emc). 16 January 2020. Archived from the original on 28 March 2020. Retrieved 28 March 2020.
  3. ^ "UK Ibrutinib label". UK Electronic Medicines Compendium. 25 August 2016. Archived from the original on 30 July 2019. Retrieved 3 October 2021.
  4. ^ a b c d e f g h i j "Imbruvica- ibrutinib capsule Imbruvica- ibrutinib tablet, film coated". DailyMed. 8 April 2020. Archived from the original on 12 August 2020. Retrieved 21 April 2020.
  5. ^ a b c d e f "Imbruvica EPAR". European Medicines Agency (EMA). 8 July 2021. Archived from the original on 10 April 2021. Retrieved 14 July 2021.
  6. ^ "Ibrutinib Monograph for Professionals". Drugs.com. Archived from the original on 10 July 2020. Retrieved 24 November 2021.
  7. ^ World Health Organization (2021). World Health Organization model list of essential medicines: 22nd list (2021). Geneva: World Health Organization. hdl:10665/345533. WHO/MHP/HPS/EML/2021.02.
  8. ^ "Ibrutinib: FDA-Approved Drugs". U.S. Food and Drug Administration (FDA). Archived from the original on 24 June 2021. Retrieved 19 June 2021.
  9. ^ BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 1028. ISBN 978-0857114105.
  10. ^ "Imbruvica Prices, Coupons & Patient Assistance Programs". Drugs.com. Archived from the original on 13 September 2021. Retrieved 24 November 2021.
Retrieved from "https://en.wikipedia.org/w/index.php?title=User:Mr._Ibrahem/Ibrutinib&oldid=1198154363"